{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T06:05:16Z","timestamp":1782281116531,"version":"3.54.5"},"posted":{"date-parts":[[2025,8,1]]},"group-title":"Immunology","reference-count":78,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.biorxiv.org\/about\/FAQ#license"}],"funder":[{"name":"National Institutes of Health (NIH)\/National Institute of General Medical Sciences","award":["R35GM142743"],"award-info":[{"award-number":["R35GM142743"]}]},{"name":"Purdue Institute for Drug Discovery (PIDD) Drug Advisory Board Grant"},{"name":"National Institutes of Health (NIH)\/National Institute of General Medical Sciences","award":["R35GM146786"],"award-info":[{"award-number":["R35GM146786"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,8,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>\n                  Cancer vaccines targeting patient-derived neoantigens offer great promise for personalized cancer therapy but face challenges in achieving targeted delivery to antigen-presenting cells (APCs) to elicit robust and durable cancer-specific immune responses. We synthesized an anti-mouse CD40 agonistic-monovalent streptavidin fusion antibody (\u03b1CD40-mSAs), which enables targeted delivery of biotinylated neoantigen peptides to APCs in draining lymph nodes (dLNs). We confirmed mSA expression on the engineered antibody and its strong binding affinities to mouse CD40 and biotin. Advanced microscopy demonstrated that \u03b1CD40-mSAs enhances homing to dLNs and intracellular delivery of neoantigen peptides to critical APC subsets, such as cDC1. The potent agonistic effects of \u03b1CD40-mSAs on dendritic cell maturation, activation, and antigen presentation were verified through\n                  <jats:italic>in vitro<\/jats:italic>\n                  assays. Vaccination with \u03b1CD40-mSAs elicited robust cancer-specific CD8\u207a T cell responses, leading to significant tumor regression and prevention in a mouse tumor model. These results support \u03b1CD40-mSAs as an \u2018all-in-one\u2019 vaccine delivery platform with multifunctional immunopharmacological advantages and strong translational potential for personalized cancer vaccination.\n                <\/jats:p>\n                <jats:sec>\n                  <jats:title>Teaser<\/jats:title>\n                  <jats:p>\u03b1CD40-mSAs is an engineered anti-CD40 agonistic antibody designed to enhance cancer vaccine delivery.<\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2025.07.30.663779","type":"posted-content","created":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T06:30:11Z","timestamp":1754116211000},"source":"Crossref","is-referenced-by-count":0,"title":["CD40 agonistic-monovalent streptavidin fusion antibody for targeted neoantigen peptide delivery and potent cancer vaccination"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0593-3657","authenticated-orcid":false,"given":"Dahee","family":"Jung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziye","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal T","family":"Ramseier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Oe","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1349-3759","authenticated-orcid":false,"given":"Steve Seung-Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2025080600050498000_2025.07.30.663779v2.1","doi-asserted-by":"crossref","unstructured":"N. Xie , G. Shen , W. Gao , Z. Huang , C. Huang , L. Fu , Neoantigens: promising targets for cancer therapy. Signal Transduct. Target. Ther. 8, 9 (2023).","DOI":"10.1038\/s41392-022-01270-x"},{"key":"2025080600050498000_2025.07.30.663779v2.2","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.vaccine.2016.05.073","article-title":"Personalized cancer vaccines: Targeting the cancer mutanome","volume":"35","year":"2017","journal-title":"Vaccine"},{"key":"2025080600050498000_2025.07.30.663779v2.3","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3105"},{"key":"2025080600050498000_2025.07.30.663779v2.4","doi-asserted-by":"crossref","unstructured":"D.-W. Wu , S.-P. Jia , S.-J. Xing , H. Ma , X. Wang , Q.-Y. Tang , Z.-W. Li , Q. Wu , M. Bai , X.-Y. Zhang , X.-F. Fu , M.-M. Jia , Y. Tang , L. Chen , N. Li , Personalized neoantigen cancer vaccines: current progression, challenges and a bright future. Clin. Exp. Med. 24, 229 (2024).","DOI":"10.1007\/s10238-024-01436-7"},{"key":"2025080600050498000_2025.07.30.663779v2.5","doi-asserted-by":"crossref","unstructured":"W. Xiao , W. Jiang , Z. Chen , Y. Huang , J. Mao , W. Zheng , Y. Hu , J. Shi , Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines. Signal Transduct. Target. Ther. 10, 74 (2025).","DOI":"10.1038\/s41392-024-02107-5"},{"key":"2025080600050498000_2025.07.30.663779v2.6","doi-asserted-by":"crossref","unstructured":"S. Qin , X. Tang , Y. Chen , K. Chen , N. Fan , W. Xiao , Q. Zheng , G. Li , Y. Teng , M. Wu , X. Song , mRNA-based therapeutics: powerful and versatile tools to combat diseases. Signal Transduct. Target. Ther. 7, 166 (2022).","DOI":"10.1038\/s41392-022-01007-w"},{"key":"2025080600050498000_2025.07.30.663779v2.7","doi-asserted-by":"crossref","unstructured":"K. Me , H. St , A.-B. H. B. A, T. Kk , H. Mmb , C. Eh, Scope and challenges of nanoparticle-based mRNA delivery in cancer treatment. Arch. Pharm. Res. 45 (2022).","DOI":"10.1007\/s12272-022-01418-x"},{"key":"2025080600050498000_2025.07.30.663779v2.8","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2373"},{"key":"2025080600050498000_2025.07.30.663779v2.9","doi-asserted-by":"crossref","unstructured":"L. Buonaguro , M. Tagliamonte , Peptide-based vaccine for cancer therapies. Front. Immunol. 14, 1210044 (2023).","DOI":"10.3389\/fimmu.2023.1210044"},{"key":"2025080600050498000_2025.07.30.663779v2.10","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08507-5"},{"key":"2025080600050498000_2025.07.30.663779v2.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.08.053"},{"key":"2025080600050498000_2025.07.30.663779v2.12","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1158\/2159-8290.CD-24-0934","article-title":"PGV001, a multi-peptide personalized neoantigen vaccine platform: Phase I study in patients with solid and hematologic malignancies in the adjuvant setting","volume":"15","year":"2025","journal-title":"Cancer Discov"},{"key":"2025080600050498000_2025.07.30.663779v2.13","doi-asserted-by":"crossref","unstructured":"D. Liu , L. Liu , X. Li , S. Wang , G. Wu , X. Che , Advancements and challenges in peptide-based cancer vaccination: A multidisciplinary perspective. Vaccines 12, 950 (2024).","DOI":"10.3390\/vaccines12080950"},{"key":"2025080600050498000_2025.07.30.663779v2.14","doi-asserted-by":"publisher","DOI":"10.1038\/nri1670"},{"key":"2025080600050498000_2025.07.30.663779v2.15","doi-asserted-by":"crossref","unstructured":"Y. Ding , Z. Li , A. Jaklenec , Q. Hu , Vaccine delivery systems toward lymph nodes. Adv. Drug Deliv. Rev. 179, 113914 (2021).","DOI":"10.1016\/j.addr.2021.113914"},{"key":"2025080600050498000_2025.07.30.663779v2.16","doi-asserted-by":"crossref","unstructured":"Z.-B. Wang , J. Xu , Better adjuvants for better vaccines: Progress in adjuvant delivery systems, modifications, and adjuvant-antigen codelivery. Vaccines 8, 128 (2020).","DOI":"10.3390\/vaccines8010128"},{"key":"2025080600050498000_2025.07.30.663779v2.17","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0607"},{"key":"2025080600050498000_2025.07.30.663779v2.18","doi-asserted-by":"publisher","DOI":"10.1038\/nature12978"},{"key":"2025080600050498000_2025.07.30.663779v2.19","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.actbio.2024.12.039","article-title":"Impact of nanoparticle properties on immune cell interactions in the lymph node","volume":"193","year":"2025","journal-title":"Acta Biomater"},{"key":"2025080600050498000_2025.07.30.663779v2.20","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200737984"},{"key":"2025080600050498000_2025.07.30.663779v2.21","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ddtec.2005.05.006","article-title":"Subcutaneous drug delivery and the role of the lymphatics","volume":"2","year":"2005","journal-title":"Drug Discov. Today Technol"},{"key":"2025080600050498000_2025.07.30.663779v2.22","doi-asserted-by":"publisher","DOI":"10.1038\/nmat3775"},{"key":"2025080600050498000_2025.07.30.663779v2.23","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41392-023-01557-7","article-title":"Vaccine adjuvants: mechanisms and platforms","volume":"8","year":"2023","journal-title":"Signal Transduct. Target. Ther"},{"key":"2025080600050498000_2025.07.30.663779v2.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2012.12.031"},{"key":"2025080600050498000_2025.07.30.663779v2.25","doi-asserted-by":"publisher","DOI":"10.1038\/nmat4822"},{"key":"2025080600050498000_2025.07.30.663779v2.26","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0390-x"},{"key":"2025080600050498000_2025.07.30.663779v2.27","doi-asserted-by":"crossref","first-page":"6845","DOI":"10.1021\/acsnano.3c04471","article-title":"A cancer nanovaccine for co-delivery of peptide neoantigens and optimized combinations of STING and TLR4 agonists","volume":"18","year":"2024","journal-title":"ACS Nano"},{"key":"2025080600050498000_2025.07.30.663779v2.28","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20032220"},{"key":"2025080600050498000_2025.07.30.663779v2.29","first-page":"232r","article-title":"Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205","volume":"6","year":"2014","journal-title":"Sci. Transl. Med"},{"key":"2025080600050498000_2025.07.30.663779v2.30","first-page":"e87102","article-title":"Targeting CLEC9A delivers antigen to human CD141+ DC for CD4+ and CD8+T cell recognition","volume":"1","year":"2016","journal-title":"JCI Insight"},{"key":"2025080600050498000_2025.07.30.663779v2.31","doi-asserted-by":"crossref","first-page":"e000691","DOI":"10.1136\/jitc-2020-000691","article-title":"Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141+ dendritic cells to activate na\u00efve and memory NY-ESO-1-specific CD8+ T cells","volume":"8","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"2025080600050498000_2025.07.30.663779v2.32","doi-asserted-by":"crossref","unstructured":"M. K. Hossain , K. A. Wall , Use of dendritic cell receptors as targets for enhancing anti-cancer immune responses. Cancers 11, 418 (2019).","DOI":"10.3390\/cancers11030418"},{"key":"2025080600050498000_2025.07.30.663779v2.33","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/mt.2011.57","article-title":"Engineering dendritic cells to enhance cancer immunotherapy","volume":"19","year":"2011","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther"},{"key":"2025080600050498000_2025.07.30.663779v2.34","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-062518-045435"},{"key":"2025080600050498000_2025.07.30.663779v2.35","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.16.1.111"},{"key":"2025080600050498000_2025.07.30.663779v2.36","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2147\/ITT.S163614","article-title":"Multiple effects of CD40-CD40L axis in immunity against infection and cancer","volume":"7","year":"2018","journal-title":"ImmunoTargets Ther"},{"key":"2025080600050498000_2025.07.30.663779v2.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.uct.2007.06.001"},{"key":"2025080600050498000_2025.07.30.663779v2.38","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/14712598.2024.2357714","article-title":"Next-generation CD40 agonists for cancer immunotherapy","volume":"24","year":"2024","journal-title":"Expert Opin. Biol. Ther"},{"key":"2025080600050498000_2025.07.30.663779v2.39","doi-asserted-by":"publisher","DOI":"10.1172\/JCI125740"},{"key":"2025080600050498000_2025.07.30.663779v2.40","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-2272-7_12"},{"key":"2025080600050498000_2025.07.30.663779v2.41","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1021\/jacsau.2c00617","article-title":"Enzymatic bioconjugation: A perspective from the pharmaceutical industry","volume":"3","year":"2023","journal-title":"JACS Au"},{"key":"2025080600050498000_2025.07.30.663779v2.42","doi-asserted-by":"publisher","DOI":"10.1021\/bi2010366"},{"key":"2025080600050498000_2025.07.30.663779v2.43","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-380121"},{"key":"2025080600050498000_2025.07.30.663779v2.44","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2017.1323159"},{"key":"2025080600050498000_2025.07.30.663779v2.45","doi-asserted-by":"crossref","first-page":"e1019198","DOI":"10.1080\/2162402X.2015.1019198","article-title":"Cross-presentation of cutaneous melanoma antigen by migratory XCR1+CD103\u2212 and XCR1+CD103+ dendritic cells","volume":"4","year":"2015","journal-title":"Oncoimmunology"},{"key":"2025080600050498000_2025.07.30.663779v2.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2010.12.011"},{"key":"2025080600050498000_2025.07.30.663779v2.47","doi-asserted-by":"crossref","unstructured":"R. G. Bouma , A. Z. Wang , J. M. M. den Haan , Exploring CD169+ macrophages as key targets for vaccination and therapeutic interventions. Vaccines 13, 330 (2025).","DOI":"10.3390\/vaccines13030330"},{"key":"2025080600050498000_2025.07.30.663779v2.48","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e318165f5d2"},{"key":"2025080600050498000_2025.07.30.663779v2.49","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.12.8576"},{"key":"2025080600050498000_2025.07.30.663779v2.50","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0157"},{"key":"2025080600050498000_2025.07.30.663779v2.51","doi-asserted-by":"crossref","unstructured":"Y. Zhang , Z. Ma , Y. Wang , J. Boyer , G. Ni , L. Cheng , S. Su , Z. Zhang , Z. Zhu , J. Qian , L. Su , Q. Zhang , B. Damania , P. Liu , Streptavidin promotes DNA binding and activation of cGAS to enhance innate immunity. iScience 23, 101463 (2020).","DOI":"10.1016\/j.isci.2020.101463"},{"key":"2025080600050498000_2025.07.30.663779v2.52","doi-asserted-by":"publisher","DOI":"10.1038\/nature14001"},{"key":"2025080600050498000_2025.07.30.663779v2.53","doi-asserted-by":"crossref","unstructured":"B. J. Hos , M. G. M. Camps , J. van den Bulk , E. Tondini , T. C. van den Ende , D. Ruano , K. Franken , G. M. C. Janssen , A. Ru , D. V. Filippov , R. Arens , P. A. van Veelen , N. Miranda , F. Ossendorp , Identification of a neo-epitope dominating endogenous CD8 T cell responses to MC-38 colorectal cancer. Oncoimmunology 9, 1673125 (2019).","DOI":"10.1080\/2162402X.2019.1673125"},{"key":"2025080600050498000_2025.07.30.663779v2.54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.09.038"},{"key":"2025080600050498000_2025.07.30.663779v2.55","doi-asserted-by":"publisher","DOI":"10.1172\/JCI80009"},{"key":"2025080600050498000_2025.07.30.663779v2.56","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.11.069"},{"key":"2025080600050498000_2025.07.30.663779v2.57","doi-asserted-by":"crossref","unstructured":"T. A. Doan , T. Forward , B. A. J. Tamburini , Trafficking and retention of protein antigens across systems and immune cell types. Cell. Mol. Life Sci. 79, 275 (2022).","DOI":"10.1007\/s00018-022-04303-4"},{"key":"2025080600050498000_2025.07.30.663779v2.58","first-page":"257","article-title":"Monoclonal antitumor antibodies in the lymphatics","volume":"68","year":"1984","journal-title":"Cancer Treat. Rep"},{"key":"2025080600050498000_2025.07.30.663779v2.59","doi-asserted-by":"crossref","unstructured":"T. Tang , X. Cheng , B. Truong , L. Sun , X. Yang , H. Wang , Molecular basis and therapeutic implications of CD40\/CD40L immune checkpoint. Pharmacol. Ther. 219, 107709 (2021).","DOI":"10.1016\/j.pharmthera.2020.107709"},{"key":"2025080600050498000_2025.07.30.663779v2.60","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.cytogfr.2023.11.002","article-title":"Harnessing the potential of CD40 agonism in cancer therapy","volume":"75","year":"2024","journal-title":"Cytokine Growth Factor Rev"},{"key":"2025080600050498000_2025.07.30.663779v2.61","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.7.4169"},{"key":"2025080600050498000_2025.07.30.663779v2.62","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20121251"},{"key":"2025080600050498000_2025.07.30.663779v2.63","doi-asserted-by":"crossref","first-page":"10079","DOI":"10.1007\/s00253-018-9377-7","article-title":"Functional expression of monomeric streptavidin and fusion proteins in Escherichia coli: applications in flow cytometry and ELISA","volume":"102","year":"2018","journal-title":"Appl. Microbiol. Biotechnol"},{"key":"2025080600050498000_2025.07.30.663779v2.64","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-1759(96)00173-1"},{"key":"2025080600050498000_2025.07.30.663779v2.65","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioeng.2007.02.003"},{"key":"2025080600050498000_2025.07.30.663779v2.66","doi-asserted-by":"crossref","unstructured":"G. Vidarsson , G. Dekkers , T. Rispens , IgG subclasses and allotypes: from structure to effector functions. Front. Immunol. 5, 520 (2014).","DOI":"10.3389\/fimmu.2014.00520"},{"key":"2025080600050498000_2025.07.30.663779v2.67","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.tips.2018.07.007","article-title":"Targeting FcRn to generate antibody-based therapeutics","volume":"39","year":"2018","journal-title":"Trends Pharmacol. Sci"},{"key":"2025080600050498000_2025.07.30.663779v2.68","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-018-0196-9"},{"key":"2025080600050498000_2025.07.30.663779v2.69","doi-asserted-by":"crossref","unstructured":"J. Zheng , Y.-C. Wu , X. Cai , P. Phan , M. Gill , E. E. Er , Z. Zhao , Z. J. Wang , S. S.-Y. Lee , Correlative multiscale 3D imaging of mouse primary and metastatic tumors by sequential light sheet and confocal fluorescence microscopy. iScience 28, 111934 (2025).","DOI":"10.1016\/j.isci.2025.111934"},{"key":"2025080600050498000_2025.07.30.663779v2.70","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1038\/s41467-025-58779-2","article-title":"Unveiling cellular communications through rapid pan-membrane-protein labeling","volume":"16","year":"2025","journal-title":"Nat. Commun"},{"key":"2025080600050498000_2025.07.30.663779v2.71","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2567.2003.01634.x"},{"key":"2025080600050498000_2025.07.30.663779v2.72","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1102390"},{"key":"2025080600050498000_2025.07.30.663779v2.73","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0128"},{"key":"2025080600050498000_2025.07.30.663779v2.74","doi-asserted-by":"crossref","unstructured":"V. Ceglia , S. Zurawski , M. Montes , M. Kroll , A. Bouteau , Z. Wang , J. Ellis , B. Z. Igy\u00e1rt\u00f3 , Y. L\u00e9vy , G. Zurawski , Anti-CD40 antibody fused to CD40 ligand is a superagonist platform for adjuvant intrinsic DC-targeting vaccines. Front. Immunol. 12, 786144 (2022).","DOI":"10.3389\/fimmu.2021.786144"},{"key":"2025080600050498000_2025.07.30.663779v2.75","doi-asserted-by":"crossref","first-page":"9542","DOI":"10.1038\/s41467-024-53839-5","article-title":"A bispecific CD40 agonistic antibody allowing for antibody-peptide conjugate formation to enable cancer-specific peptide delivery, resulting in improved T Cell proliferation and anti-tumor immunity in mice","volume":"15","year":"2024","journal-title":"Nat. Commun"},{"key":"2025080600050498000_2025.07.30.663779v2.76","doi-asserted-by":"crossref","unstructured":"M. Eltahir , I. Laur\u00e9n , M. Lord , A. Chourlia , L. Dahllund , A. Olsson , A. Saleh , A. J. Ytterberg , A. Lindqvist , O. Andersson , H. Persson , S. M. Mangsbo , An adaptable antibody-based platform for flexible synthetic peptide delivery built on agonistic CD40 antibodies. Adv. Ther. 5, 2200008 (2022).","DOI":"10.1002\/adtp.202200008"},{"key":"2025080600050498000_2025.07.30.663779v2.77","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2537-9"},{"key":"2025080600050498000_2025.07.30.663779v2.78","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02851-9"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2025.07.30.663779","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T05:16:15Z","timestamp":1782278175000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2025.07.30.663779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":78,"URL":"https:\/\/doi.org\/10.1101\/2025.07.30.663779","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1016\/j.jconrel.2026.115053","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2025,8,1]]},"subtype":"preprint"}}